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Abstract: Objective: This study was conducted to investigate the
efﬁcacy and safety of using a concurrent neoadjuvant chemoradiother-
apy (a XELOX regimen) to treat adenocarcinoma of the gastroesoph-
ageal junction. Methods: Seventy-six patients having resectable
adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were
recruited to participate and randomly assigned to either a chemoradio-
therapy group or a surgery group. Patients in the chemoradiotherapy
group were orally given capecitabine (1,000 mg/m2, twice daily for 14
days, days 1–14) and intravenous oxaliplatin (130 mg/m2 on day 1) for
2 cycles. Radiotherapy was performed with a total of 45 Gy adminis-
tered in 25 sessions for 5 weeks. Patients in the surgery group received
only surgical intervention. Results: In the concurrent chemoradiother-
apy group, the overall response rate was 55.6% (20/36), tumor control
rate was 100% and a pathological complete response was achieved in
16.7% (6/36). The entire chemoradiotherapy group had R0 resections as
did 80% of the surgery group (32/40) (P , 0.05). In the concurrent
chemoradiotherapy group, 6 patients developed grade 3 side effects.
Treatment was either discontinued or the dose adjusted. Major hemato-
logical side effects in the chemoradiotherapy group included leukopenia,
neutropenia, anemia and thrombocytopenia. Nonhematological side ef-
fects included nausea, vomiting and appetite loss. Chemoradiotherapy-
related death was not observed. Conclusions: Concurrent neoadjuvant
chemoradiotherapy administration increased the rate of R0 resection and
demonstrated favorable safety in patients with Siewert II or III
adenocarcinoma at the gastroesophageal junction. These results support
the use of neoadjunctive chemoradiotherapy in the treatment of
adenocarcinoma of the gastroesophageal junction.
Key Indexing Terms: Neoadjuvant chemoradiotherapy; Gastroesoph-
ageal junction; Treatment. [Am J Med Sci 2015;349(6):472–476.]
T herapeutic modalities for esophageal cancer have pro-gressed from surgery alone to surgery combined with radio-
therapy, chemotherapy and/or targeted therapy. Compared with
surgery alone, concurrent neoadjuvant chemoradiotherapy may
signiﬁcantly increase the radical resection rate and improve the
prognosis of esophageal1,2 and rectal cancer patients.3 However,
debate still exists regarding gastroesophageal junction
adenocarcinoma therapy selection.4,5 Some clinical studies6,7
show that preoperative concurrent neoadjuvant chemoradiother-
apy may result in increased pathological complete response and
R0 resection rates with tolerable side effects, such as lower neg-
ative pathological nodes.6 However, most of these studies were
conducted in the United States and Europe.8 Researchers in
Western countries found that obesity and frequent reﬂux in com-
bination were associated with considerably higher risk for gas-
troesophageal junction adenocarcinoma than either single factor
alone. Comparing with Eastern countries, shifts in dietary
practices in recent decades toward increased fat intake and
consumption of meats in Western countries may have contrib-
uted in part to the rising incidence of gastroesophageal
junction adenocarcinoma.9 Therefore, few studies have inves-
tigated the efﬁcacy of neoadjuvant chemoradiotherapy in
Asians with adenocarcinoma gastroesophageal junction ad-
enocarcinomas. In this study, patients having adenocarcinoma
located at the gastroesophageal junction were recruited from
Hebei Province, China, and received concurrent neoadjuvant




A total of 76 patients with resectable adenocarcinoma at
the gastroesophageal junction (T3/4, N+, M0) were recruited at
the Fourth Hospital of Hebei Medical University, China,
between August 2012 and August 2013. Each was randomly
assigned to one of 2 groups: a concurrent chemoradiotherapy
group (n 5 36) or a surgery group (n 5 40). Patients in the
concurrent chemoradiotherapy group (32 men and 4 women,
median age: 61 years, range: 46–73 years) received concurrent
chemoradiotherapy and subsequent surgery. Patients in the sur-
gery group (32 men and 8 women, median age: 57 years, range:
42–72 years) were treated with surgery alone. The general clin-
ical characteristics of patients in the 2 groups are shown in
Table 1. This study was approved by the Ethics Committee
of the Fourth Hospital of Hebei Medical University and was
registered at ClinicalTrials.gov (NCT01962246).
Patient-inclusion criteria for this study were as follows: (1)
conﬁrmation, by gastroscopy and CT, of Siewert II or III
adenocarcinoma of the gastroesophageal junction with a pre-
surgery tumor long diameter of #8 cm; (2) presurgery classiﬁ-
cation as progressive gastric cancer (T3/4, N+, M0) using the
American Joint Committee on Cancer (American Joint Commit-
tee on Cancer, AJCC) 2010 patient classiﬁcation with no evi-
dence of metastasis to the liver, lung, brain, bone or other organs;
(3) no prior antitumor therapy; (4) no contraindications for che-
motherapy or surgery; (5) a Karnofsky Performance Status (KPS)
score of .60 and an Eastern Cooperative Oncology Group
(ECOG) score of 0 to 2 and (6) informed consent obtained before
enrollment.
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Chemotherapy Regimen
The following XELOX regimen was used. Capecita-
bine was administered 1,000 mg/m2 twice daily for 14 days
(days 1–14), and oxaliplatin was given intravenously 130 mg/m2
on day 1 for 2 cycles. Two chemotherapy cycles were adminis-
tered before surgery and 6 cycles after.
Radiotherapy Regimen
Concurrent CT-based 3-dimensional conformal radio-
therapy was delivered by a linear accelerator as multiple shaped
beams of 6 to 20 MV X-rays in 5 daily fractions of 1.8 Gy per
week for 5 weeks (total dose: 45 Gy). The biologically effective
dose, calculated using the linear-quadratic formalism and an
a/b ratio of 10 for early responding-tissues (tumor), was 51.1
Gy. According to tolerance of different patients, the chosen
dosage ranged from 50 to 52 Gy.
Radiation targets included the entire adenocarcinoma of
gastroesophageal junction, any perigastric extension and
lymph nodes (gastric, celiac, porta hepatis, gastroduodenal,
splenic-suprapancreatic and retropancreatic-duodenal), with
adequate margins. The distal margins of the esophagus (3–5 cm)
were included when the tumor involved the gastroesophageal
junction.
Therapeutic Efficacy Determinations
Therapeutic efﬁcacy was determined according to the
Response Evaluation Criteria In Solid Tumors (RECIST
Version 1.1) and included the following categories: complete
response (CR), partial response (PR), stable disease (SD) and
progressive disease. The response rate (RR) was calculated as
the sum of CR and PR. The tumor control rate was calculated as
the sum of CR, PR and SD. Tumor node metastasis (TNM)
staging was performed according to the criteria developed by
American Joint Committee on Cancer (7th edition).
Surgery
Surgical treatment consisted of either (1) proximal
subtotal gastrectomy or (2) total gastrectomy and a subsequent
extended lymph node dissection (D2 resection).
Pathological Analysis
Pathological examinations included detecting tumor;
invasion depth; number of metastatic lymph nodes; surgical
margins; human epidermal growth factor receptor-2 HER-2
expression and tumor regression grade (TRG).
Tumor regression grades were deﬁned as follows: grade 0
(complete remission) is no cancer cells. Grade 1 (partial
remission) is single cells or small groups of cancer cells.
Grade 2 (low efﬁcacy) is residual cancer outgrown by ﬁbrosis.
Grade 3 (poor efﬁcacy) is minimal or no treatment effect and
extensive residual cancer cells.
Statistical Analysis
Statistical analysis was performed using SPSS version
19.0 software. Quantitative data comparisons were made using
the x2 test. Qualitative data were expressed as the mean 6 SD




RECIST1.1 evaluation of the concurrent chemoradio-
therapy group evaluation showed CR in 0 patients, PR in 20
patients, SD in 16 patients and progressive disease in 0 patients.
RR in the concurrent chemoradiotherapy group was 55.6%
(20/36). The tumor control rate was 100%. A clinical stage
reduction was noted in 61.1% (22/36) of patients.
Safety Evaluation
Toxic Effects of Concurrent Chemoradiotherapy
Concurrent chemoradiotherapy toxic effects were evalu-
ated using the National Cancer Institute Common Toxicity
Criteria (NCI-CTC) version 4.0. Nonhematologic toxic effects
included nausea, vomiting, loss of appetite, abnormal liver
function, neurological toxicity and radiation dermatitis. Hema-
tologic toxic effects included leukopenia, neutropenia, anemia
and thrombocytopenia. These toxic effects were graded 1 to 2
primarily and resolved after symptomatic therapy. There were
no chemotherapy-related deaths (Table 2). Treatment was tem-
porarily discontinued for 6 patients due to grade 3 toxic effects
and restarted after the toxic effects had lessened or resolved.
Chemotherapeutic dosages was reduced for 4 patients.
Perioperative Complications
One patient in a concurrent chemoradiotherapy group
developed a lymphatic ﬁstula which resolved after 5 days of
conservative therapy. One developed moderate pleural effusion
and ascites. These symptoms were signiﬁcantly improved after











M 32 (88.9) 32 (80)
F 4 (11.1) 8 (20)
Degree of tumor
differentiation, n (%)
Moderately differentiated 14 (38.9) 18 (45)
Poorly differentiated 16 (44.4) 18 (45)
Mucinous adenocarcinoma 6 (16.7) 4 (10)





0 10 (27.8) 16 (40)
1+ 14 (38.9) 16 (40)
2+ (FISH: negative) 10 (27.8) 6 (15)
3+ (or FISH: positive) 2 (5.5) 2 (5)
Clinical T stage, n (%)
cT3 14 (38.9) 16 (40)
cT4 22 (61.1) 24 (60)
Clinical N stage, n (%)
cN0 12 (33.3) 16 (40)
cN1 18 (50) 18 (45)
cN2 6 (16.7) 6 (15)
ECOG score, n (%)
0 4 (11.1) 8 (20)
1 28 (77.8) 24 (60)
2 4 (11.1) 8 (20)
Neoadjuvant Chemoradiotherapy
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13 days of conservative therapy. One surgery group patient
developed an esophageal jejunal anastomotic ﬁstula that
resolved after 52 days of conservative therapy. One patient
had a wound dehisce, which resolved after symptomatic
therapy. In the concurrent chemoradiotherapy group, a jejunal
tube was indwelt for a month after surgery to ensure early and
smooth enteral nutrition.
Surgery
In the neoadjuvant chemoradiotherapy group, surgery was
performed after concurrent chemoradiotherapy. The median
interval between concurrent chemoradiotherapy and surgery
was 6.7 weeks (range: 5.7–8 weeks). Peritoneal cytology results
were negative for both groups. The concurrent chemoradiother-
apy group consisted of 36 participants who had the following
interventions performed at the rates and number of participants
indicated: proximal subtotal gastrectomy and jejunal interposition
surgery 44.4% (16/36); proximal subtotal gastrectomy and an
esophageal gastric remnant anastomosis was performed in
11.1% (4/36); total gastrectomy and Roux-en-Y anastomosis
33.3% (12/36); total gastrectomy and jejunal interposition
11.1% (4/36). The surgery group consisted of 40 patients. The
following interventions were performed at the rates and number
of participants noted: proximal subtotal gastrectomy and jejunal
interposition surgery 45% (18/40); proximal subtotal gastrectomy
and esophageal gastric remnant anastomosis 15% (6/40); total
gastrectomy and Roux-en-Y anastomosis 40% (16/40).
Pathological Evaluation
R0 resection rates in the concurrent chemoradiotherapy
group and the surgery group were 100% and 80% (32/40),
respectively. This difference is statistically signiﬁcant (x2 5
4.024, P 5 0.045). In the concurrent chemoradiotherapy group,
the pathological complete RR was 16.7% (6/36), and the total
pathological RR (grade 1 + grade 0) was 72.2% (26/36), which
was statistically signiﬁcant (P , 0.05). The number of resect
lymph nodes in the concurrent chemoradiotherapy group and
the surgery group was 26.9 6 8.4 and 29.4 6 9.2, respectively.
This difference was not statistically signiﬁcant (t 5 1.725, P .
0.05). Lymph node metastasis occurred in 2.5% (24/968) of the
concurrent chemoradiotherapy group and in 7.1% (84/1,176) of
the surgery group. This difference is statistically signiﬁcant
(x2 5 12.070, P 5 0.001).
DISCUSSION
Siewert has 3 classiﬁcations of gastroesophageal junction
adenocarcinomas.10,11 The surgery recommended as treatment
varies with each. Patient with Siewert II and III adenocarcinomas
are less likely to have upper and middle mediastinal lymph node
metastasis making surgery using the transabdominal approach by
the diaphragmatic hiatus feasible. In neoadjuvant therapy, pre-
operative concurrent chemoradiotherapy efﬁcacy in treating Sie-
wert II and III gastric cancers has been previously conﬁrmed in
clinical trials conducted in Western countries. However, the
necessity for neoadjuvant therapy has not been conﬁrmed.12–14
Patients with adenocarcinoma of the gastroesophageal junction
were not separated from those with esophageal, or gastric, cancer
in most of these studies. The authors were able to identify on
a few studies that seem to have been conducted investigating
adenocarcinoma at the gastroesophageal junction. This lack of
clinical data might result in inappropriate use of combined che-
motherapy drugs or radiotherapy dose.
The MAGIC trial, which compared the therapeutic
efﬁcacy of cisplatin-based neoadjuvant chemotherapy and
surgery alone, resulted in encouraging ﬁndings regarding the
utility of neoadjuvant therapy.15 That study showed a 5-year
survival rate for patients receiving neoadjuvant chemotherapy
increased by 13% compared with a surgery group (36% versus
23%). Patients with type II and III adenocarcinoma of the
esophagogastric junction accounted for only 11.5% (58/503)
of the total subjects studied, but the ﬁndings relating to using
neoadjuvant therapy to treat esophagogastric junction adenocar-
cinomas were encouraging.16,17 As a result, focal radiotherapy
was added to systemic chemotherapy with the goal of improv-
ing therapeutic efﬁcacy. An RR of 55.6%, total tumor control
rate of 100% and clinical stage reduction rate of 61.1% suggest
that the therapeutic efﬁcacy of concurrent chemoradiotherapy
was superior to surgery alone.18,19 These ﬁndings were consis-
tent with those of De Paoli et al as an interim analysis of a phase
II multicenter study presented at a European Society for Med-
ical Oncology conference.20
The timely implementation of radical resection of the
cancer is a key step toward a favorable therapeutic result.
Radiotherapy may lessen the focal inﬂammatory edema and
ﬁbrous adhesion of the tumor after chemotherapy. Surgery was
performed 6 weeks after chemoradiotherapy.
Among the surgical modalities available for resecting
esophagogastric junction adenocarcinoma, proximal subtotal
gastrectomy seems to have achieved the best radical resection
of the cancer. Preoperative evaluation usually shows that the
cancer to be localized at the esophagogastric junction. The choice
of surgical modality should be made according to intraoperative
exploration ﬁndings.21,22 For example, if there is extensive lymph
node enlargement at the lesser curvature of the stomach and the
TABLE 2. Toxic effects of concurrent chemoradiotherapy in 36 patients, n (%)
Toxic effects Grade 1 Grade 2 Grade 3 Grade 4 Grand total
Hematologic
Leukopenia 16 (44.4) 6 (16.7) 2 (5.6) 0 24 (66.7)
Neutropenia 8 (22.2) 6 (16.7) 0 0 14 (38.9)
Anemia 4 (11.1) 2 (5.6) 0 0 6 (16.7)
Thrombocytopenia 2 (5.6) 4 (11.1) 4 (11.1) 0 10 (27.8)
Abnormal liver function 6 (16.7) 0 0 0 6 (16.7)
Nonhematologic
Nausea 4 (11.1) 8 (22.2) 0 0 12 (33.3)
Vomiting 8 (22.2) 2 (5.6) 0 0 10 (27.8)
Loss of appetite 8 (22.2) 8 (22.2) 0 0 16 (44.4)
Neurological toxicity 2 (5.6) 0 0 0 2 (5.6)
Radiation dermatitis 2 (5.6) 0 0 0 2 (5.6)
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lower borderline of the cancer is blurred, active total gastrec-
tomy is the preferred method for achieving radical resection
of the tumor. This is also an important factor in the favorable
R0 resection rate for patients receiving concurrent chemora-
diotherapy. All the patients in this study that received
concurrent chemoradiotherapy also underwent surgical inter-
vention and achieved an R0 resection. No other previous
studies have found such results.6,14,23,24 In addition, the
pathological complete remission rate in this study was
16.7% and is consistent with previously reported results that
ranged from 15% to 30%.25–29
Some investigators have questioned the efﬁcacy of
concurrent chemoradiotherapy preceding surgery of adenocarci-
nomas of the esophagogastric junction and have also expressed
concerns about the toxic effects of such therapy. In the CROSS
study,6 1 patient receiving chemotherapy, with carboplatin plus
paclitaxel and concurrent radiotherapy at 41.4 Gy, developed
grade 4 hematologic toxicity and neutropenic fever.30 One other
patient died of possible esophageal perforation, heavy bleeding or
thrombocytopenia after chemoradiotherapy and before surgery. A
Duke University Medical Center study examined the therapeutic
efﬁcacy of chemotherapy with ﬂuorouracil in combination with
platinum or taxane, and concurrent radiotherapy at 45 Gy, in the
treatment of 48 patients with gastric adenocarcinoma or adeno-
carcinoma of the esophagogastric junction.31 In that study, ther-
apy was discontinued in 6 patients, 2 patients failed to complete
the concurrent chemoradiotherapy and 1 patient developed gas-
tric perforation and febrile neutropenia. In this study, 6 patients
developed grade 3 hematologic toxicity. Two had leukopenia and
4 had thrombocytopenia. Fever and heavy bleeding were not
observed. Chemoradiotherapy-related death was absent. During
the perioperative period for patients in this study, 1 patient devel-
oped a lymphatic ﬁstula that may have been attributable to an
accidental lymphatic injury during the surgery. A single patient
developed moderate plural effusion and ascites that might be
attributable to abnormal liver function before surgery and also
to postoperative stress. These symptoms were resolved after
active therapy. Patients in the concurrent chemoradiotherapy
group each had an indwelling jejunal feeding tube for 1 month
to assure adequate enteral nutrition, and postoperative com-
plications were reduced. The results of this study can be com-
pared with those of the INT-0116 study in which postsurgical
adjunctive concurrent chemoradiotherapy was performed.32 In
the INT-0116 study, 64% of patients completed the therapy.
Three patients experienced chemoradiotherapy-related death.
Forty-one percent developed grade 3 toxic effects and 32%
had grade 4 toxic effects. This comparison suggests that pre-
operative concurrent chemoradiotherapy is relatively safe. The
ﬁndings of this study suggest that the toxic effects of chemo-
therapy are tolerable. A XELOX regimen is administered in
combination with radiotherapy at 45 Gy (25 sessions) that
may contribute to the absence of highly toxic taxanes in the
chemotherapeutic regimen.
It should be noted that the long-term survival of
patients included in this study is unknown. On the basis of
available ﬁndings, chemotherapy with the XELOX regimen
administered in combination with radiotherapy at 45 Gy (25
sessions) seems to be a mildly toxic, but highly effective,
therapeutic modality for patients with adenocarcinoma at the
gastroesophageal junction. However, additional studies con-
ducted with larger sample sizes and careful patient monitor-
ing would be required to conﬁrm these ﬁndings. The results
of such studies could be used to signiﬁcantly improve
therapeutic efﬁcacy in treatment of adenocarcinoma of the
esophagogastric junction.
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